• 2 July 2015
    Wilson Therapeutics appoints Hans Schikan to its Board of Directors

    Wilson Therapeutics AB, a privately-held biopharmaceutical company, today announced the appointment of Hans Schikan to its board of directors. The appointment was approved by the shareholders during the Annual General Meeting on June 30.

    “We are delighted to welcome Hans to Wilson’s board of directors,” said Jonas Hansson, CEO of Wilson Therapeutics. “Hans brings significant global biopharmaceutical industry experience to Wilson, and we look forward to his contributions to the Company.”

    Hans Schikan is a pharmacist trained at Utrecht University in the Netherlands. Until very recently he was CEO of Prosensa, an RNA-modulating company developing novel therapies for rare neuromuscular and neurodegenerative disorders, which successfully completed an IPO on the US Nasdaq exchange before being acquired by BioMarin for up to $840 million. Mr Schikan is also a board member of SOBI, Hansa Medical and of the Dutch Top Sector Life Sciences & Health. He was previously a member of the Biotechnology Industry Organization’s Emerging Companies Section Governing Board and is past Chairman of Nefarma, the industry association for the Dutch branches of innovative pharmaceutical companies. Before Prosensa he held various senior management positions at Organon and Genzyme.

    “I am delighted to join Wilson during such an exciting time in the Company’s development,” said Mr. Schikan. "I look forward to leveraging my experience developing innovative products to help Wilson make a difference in the lives of people with rare diseases.”